Oral administration of a Gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression

Cancer Prevention Research

Volumn 6, Issue 9, 2013, Pages 959-970

  So, Jae Young ^a   Wahler, Joseph E ^a   Yoon, Taesook ^d   Smolarek, Amanda K ^a   Lin, Yong ^b,c   Shih, Weichung Joe ^b,c   Maehr, Hubert ^a   Uskokovic, Milan ^a   Liby, Karen T ^e   Sporn, Michael B ^e   Suh, Nanjoo ^a,c  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d Ewha Womans University   (South Korea)

^e DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYANO 3,12 DIOXOOLEANA 1,9(11) DIEN 28 OIC ACID IMIDAZOLIDE; BXL 0124; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRITERPENOID; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER PREVENTION; CONTROLLED STUDY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CALCITRIOL; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; IMIDAZOLES; MAMMARY NEOPLASMS, ANIMAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; OLEANOLIC ACID; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84883781592     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-13-0087     Document Type: Article

References (42)

1. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2012;9:16-32.
2. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;16:1647-55. (Pubitemid 27151960)
3. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54. (Pubitemid 40637826)
4. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992;23:974-9.
5. Roses RE, Paulson EC, Sharma A, Schueller JE, Nisenbaum H, Weinstein S, et al. HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev 2009;18:1386-9.
6. Pradeep CR, Zeisel A, Kostler WJ, Lauriola M, Jacob-Hirsch J, Haibe-Kains B, et al. Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions. Oncogene 2012;31:3569-83.
7. Bikle D. Nonclassic actions of vitamin D. J Steroid Biochem Mol Biol 2009;94:26-34.
8. Adams JS, Hewison M. Update in vitamin D. J Steroid Biochem Mol Biol 2010;95:471-8.
9. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007;7:684-700. (Pubitemid 47327412)
10. Zinser GM, Welsh JE. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice. Carcinogenesis 2004;25:2361-72. (Pubitemid 39625176)
11. Lee HJ, Paul S, Atalla N, Thomas PE, Lin X, Yang I, et al. Gemini vitamin D analogues inhibit estrogen receptor-positive and estrogen receptornegative mammary tumorigenesis without hypercalcemic toxicity. Cancer Prev Res 2008;1:476-84.
12. Lee HJ, So JY, DeCastro A, Smolarek A, Paul S, Maehr H, et al. Gemini vitamin D analog suppresses ErbB2-positive mammary tumor growth via inhibition of ErbB2/AKT/ERK signaling. J Steroid Biochem Mol Biol 2010;121:408.
13. Nishino H, Nishino A, Takayasu J, Hasegawa T, Iwashima A, Hirabayashi K, et al. Inhibition of the tumor-promoting action of 12-O-tetra-decanoylphorbol- 13-acetate by some oleanane-type triterpenoid compounds. Cancer Res 1988;48:5210-5.
14. Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 2007;7:357-69. (Pubitemid 46652485)
15. Konopleva M, Zhang W, Shi YX, McQueen T, Tsao T, Abdelrahim M, et al. Synthetic triterpenoid 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. Mol Cancer Ther 2006;5:317-28.
16. Bishayee A, Ahmed S, Brankov N, Perloff M. Triterpenoids as potential agents for the chemoprevention and therapy of breast cancer. Front Biosci 2011;16:980.
17. Liby K, Risingsong R, Royce DB, Williams CR, Yore MM, Honda T, et al. Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl ester and the rexinoid LG100268. Clin Cancer Res 2008;14:4556-63.
18. Kim EH, Deng C, Sporn MB, Royce DB, Risingsong R, Williams CR, et al. CDDO-Methyl ester delays breast cancer development in BRCA1-mutated mice. Cancer Prev Res 2012;5:89-97.
19. Kim EH, Deng CX, Sporn MB, Liby KT. CDDO-imidazolide induces DNA damage, G2/M arrest and apoptosis in BRCA1-mutated breast cancer cells. Cancer Prev Res 2011;4:425-34.
20. Place AE, Suh N, Williams CR, Risingsong R, Honda T, Honda Y, et al. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res 2003;9:2798-806. (Pubitemid 36842126)
21. Ji Y, Lee HJ, Goodman C, Uskokovic M, Liby K, Sporn M, et al. The synthetic triterpenoid CDDO-imidazolide induces monocytic differentiation by activating the Smad and ERK signaling pathways in HL60 leukemia cells. Mol Cancer Ther 2006;5:1452-8. (Pubitemid 44070481)
22. Maehr H, Lee HJ, Perry B, Suh N, Uskokovic MR. Calcitriol derivatives with two different side chains at C-20. V. Potent inhibitors of mammary carcinogenesis and inducers of leukemia differentiation. J Med Chem 2009;52:5505-19.
23. Honda T, Honda Y, Favaloro FG Jr, Gribble GW, Suh N, Place AE, et al. A novel dicyanotriterpenoid, 2-cyano-3,12-dioxooleana-1,9 (11)-dien-28-onitrile, active at picomolar concentrations for inhibition of nitric oxide production. Bioorg Med Chem Lett 2002;12:1027-30. (Pubitemid 34242794)
24. Sporn MB, Liby KT, Yore MM, Fu L, Lopchuk JM, Gribble GW. New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by infl ammatory and oxidative stress. J Nat Prod 2011;74:537.
25. Yates MS, Tauchi M, Katsuoka F, Flanders KC, Liby KT, Honda T, et al. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther 2007;6:154-62. (Pubitemid 46206678)
26. Lee HJ, Ju J, Paul S, So JY, DeCastro A, Smolarek A, et al. Mixed tocopherols prevent mammary tumorigenesis by inhibiting estrogen action and activating PPAR-gamma. Clin Cancer Res 2009;15:4242-9.
27. Lee HJ, Liu H, Goodman C, Ji Y, Maehr H, Uskokovic M, et al. Gene expression profiling changes induced by a novel Gemini vitamin D derivative during the progression of breast cancer. Biochem Pharmacol 2006;72:332-43. (Pubitemid 43975086)
28. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37. (Pubitemid 33674041)
29. Staal A, Van Wijnen AJ, Birkenhäger J, Pols H, Prahl J, DeLuca H, et al. Distinct conformations of vitamin D receptor/retinoid X receptor-alpha heterodimers are specifi ed by dinucleotide differences in the vitamin D-responsive elements of the osteocalcin and osteopontin genes. Mol Endocrinol 1996;10:1444-56.
30. Crowe DL, Chandraratna R. A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res 2004;6:R546-R55.
31. Townson JL, Macdonald IC, Liby KT, Mackenzie L, Dales DW, Hedley BD, et al. The synthetic triterpenoid CDDO-Imidazolide suppresses experimental liver metastasis. Clin Exp Metastasis 2011;28:309-17.
32. Liby K, Yore MM, Roebuck BD, Baumgartner KJ, Honda T, Sundararajan C, et al. A novel acetylenic tricyclic bis-(cyano enone) potently induces phase 2 cytoprotective pathways and blocks liver carcinogenesis induced by a flatoxin. Cancer Res 2008;68:6727-33.
33. Honda T, Dinkova-Kostova AT, David E, Padegimas EM, Sundararajan C, Visnick M, et al. Synthesis and biological evaluation of 1-[2-cyano-3,12- dioxooleana-1,9(11)-dien-28-oyl]-4-ethynylimidazole. A novel and highly potent anti-inflammatory and cytoprotective agent. Bioorg Med Chem Lett 2011;21:2188-91.
34. Motoyama AB, Hynes NE, Lane HA. The efficacy of ErbB receptortargeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 2002;62:3151-8. (Pubitemid 34602408)
35. Blancato J, Singh B, Liu A, Liao D, Dickson R. Correlation of amplification and overexpression of the c-myc oncogene in high-grade breast cancer: FISH, in situ hybridisation and immunohistochemical analyses. Br J Cancer 2004;90:1612-9. (Pubitemid 38648247)
36. 1 cell cycle regulators in breast tumour cells. Oncogene 2000;19:1647.
37. Berns EMJJ, Klijn JGM, van Putten WLJ, van Staveren IL, Portengen H, Foekens JA. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res 1992;52:1107-13.
38. Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004;64:8534-40. (Pubitemid 39552065)
39. Perez EA, Jenkins RB, Dueck AC, Wiktor AE, Bedroske PP, Anderson SK, et al. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol 2011;29:651-9.
40. Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, et al. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. J Natl Cancer Inst 2003;95:1825-33. (Pubitemid 38054683)
41. Strecker TE, Shen Q, Zhang Y, Hill JL, Li Y, Wang C, et al. Effect of lapatinib on the development of estrogen receptor- negative mammary tumors in mice. J Natl Cancer Inst 2009;101:107-13.
42. Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, et al. Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res 2005;65:4799-808. (Pubitemid 40740818)